

IN THE CLAIMS:

Please amend the claims as follows:

1. - 20. (Cancelled)

21. (Currently Amended) A purified or isolated antibody or ~~a functional~~-an antigen-binding fragment thereof comprising a heavy chain variable region with at least 80% identity to SEQ ID NO:5 and ~~that includes~~ comprising first, second and third complementarity determining regions (CDR1, CDR2 and CDR3), wherein CDR3 of the heavy chain variable region comprises amino acids 99-108 of SEQ ID NO:5, and a light chain variable region with at least 80% identity to the amino acid sequence of SEQ ID NO:7 and comprising first, second and third complementarity determining regions (CDR1, CDR2 and CDR3), and wherein the antibody or ~~functional~~ antigen-binding fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSM ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells.

22. (Currently Amended) The purified or isolated antibody or ~~a functional~~-an antigen-binding fragment thereof of claim 21, wherein said antibody or ~~functional~~ antigen-binding fragment thereof comprises a heavy chain variable region with at least 85% identity to the amino acid sequence of SEQ ID NO:5.

23. (Currently Amended) The purified or isolated antibody or ~~a functional~~-an antigen-binding fragment thereof of claim 22, wherein said antibody or ~~a functional~~-antigen-binding fragment thereof comprises a light chain variable region with at least 85% identity to the amino acid sequence of SEQ ID NO:7.

24. - 26. (Cancelled)

27. (Currently Amended) A purified or isolated antibody or ~~a functional~~ an antigen-binding fragment thereof comprising first, second and third complementarity determining regions (CDR1, CDR2 and CDR3), amino acids 31-35, 50-66, and 99-108, respectively of SEQ ID NO:5 or comprising first, second and third complementarity determining regions (CDR1, CDR2 and CDR3), amino acids 23-36, 52-58, and 91-101, respectively of SEQ ID NO:7, wherein the antibody or ~~functional~~ antigen-binding fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSMZ ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells.

28. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 27, wherein said antibody or ~~functional~~ antigen-binding fragment thereof comprises CDR1, CDR2 and CDR3, amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5, respectively.

29. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 27, wherein said antibody or ~~functional~~ antigen-binding fragment comprises CDR1, CDR2 and CDR3, amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7, respectively.

30. (Previously Presented) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27 wherein said antibody or ~~functional~~ antigen-binding fragment thereof specifically binds to Colo-699 (DSMZ Accession Number ACC 196), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

31. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or 27, wherein said antibody is a monoclonal antibody or a ~~functional~~ antigen-binding fragment thereof.

32. (Currently Amended) The purified or isolated ~~functional~~ antigen-binding fragment of claim 21 or 27, wherein said ~~functional~~ antigen-binding fragment is selected from the group consisting of V<sub>L</sub>, V<sub>H</sub>, F<sub>v</sub>, Fab, Fab', and F(ab')<sub>2</sub>.

33.-34. (Cancelled)

35. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or 27, comprising CDR1, CDR2 and CDR3, amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5, respectively and CDR1, CDR2 and CDR3, amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7, respectively.

36. - 46. (Cancelled)

47. (Currently Amended) The purified or isolated antibody ~~or functional fragment~~ of claims, 21 or 27 wherein said antibody is produced by the NORM-2 cell line having DSMZ deposit accession number DSM ACC2626.

48. - 88. (Cancelled)

89. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27 wherein said antibody or ~~functional~~ antigen-binding fragment comprises a heavy chain variable region at least 90% identical to SEQ ID NO:5.

90. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27 wherein said antibody or ~~functional~~ antigen-binding fragment comprises a light chain variable region at least 90% identical to SEQ ID NO:7.

91. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27 wherein said antibody or ~~functional~~ antigen-binding fragment comprises a heavy chain variable region at least 95% identical to SEQ ID NO:5.

92. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of any one of claim 21 or claim 27, wherein said antibody or ~~functional~~ antigen-binding fragment comprises a light chain variable region at least 95% identical to SEQ ID NO:7.

93. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27, wherein said antibody or ~~functional~~ antigen-binding fragment induces apoptosis of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37),

23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

94. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27, wherein said antibody or ~~functional~~ antigen-binding fragment decreases proliferation of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

95. (Currently Amended) The purified or isolated antibody or ~~functional~~ antigen-binding fragment of claim 21 or claim 27, wherein the heavy or light chain variable region has an insertion, deletion or substitution of one amino acid residue.

96. (Currently Amended) A purified or isolated antibody or a ~~functional~~ an antigen-binding fragment thereof, wherein said antibody or ~~functional~~ antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:5 and SEQ ID NO:7, each of SEQ ID NO:5 and SEQ ID NO:7 comprising first, second and third complementarity determining regions (CDR1, CDR2 and CDR3), with one amino acid insertion, deletion or substitution in either or both of SEQ ID NO:5 and SEQ ID NO:7, wherein the antibody or ~~functional~~ antigen-binding fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSM ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells.